Compare Novavax Inc (NVAX) vs Wynn Resorts, Limited (WYNN) Price & Performance

Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.

The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.

Wynn Resorts trades at $75.29, up 0.43% on the day, with a bearish technical signal from moving averages and mixed oscillators. The company reported Q2 2026 EPS of $1.24, beating expectations, driven by Macau strength, but faces margin pressure in the U.S. and rising capital expenditure for new projects. Revenue for 2025 was $7.14 billion with a net income margin of 4.58%, while the balance sheet shows high long-term debt of $10.50 billion and negative shareholder equity.

The outlook is mixed: analyst consensus is bullish with a $132.36 price target, but risks include high leverage, project costs, and competitive pressures. Upside hinges on Macau recovery and successful project execution, while downside risks stem from debt servicing and macroeconomic volatility.